HK1069205A1 - Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides - Google Patents

Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides

Info

Publication number
HK1069205A1
HK1069205A1 HK05101599A HK05101599A HK1069205A1 HK 1069205 A1 HK1069205 A1 HK 1069205A1 HK 05101599 A HK05101599 A HK 05101599A HK 05101599 A HK05101599 A HK 05101599A HK 1069205 A1 HK1069205 A1 HK 1069205A1
Authority
HK
Hong Kong
Prior art keywords
bases
apoptosis
conformation
inducing
activity relationship
Prior art date
Application number
HK05101599A
Other languages
English (en)
Inventor
Nigel C Phillips
Mario C Filion
Zdenek Richard Holan
Stephanie Reader
Original Assignee
Bioniche Life Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioniche Life Sciences Inc filed Critical Bioniche Life Sciences Inc
Publication of HK1069205A1 publication Critical patent/HK1069205A1/xx

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B99/00—Subject matter not provided for in other groups of this subclass
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/335—Modified T or U

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Medical Informatics (AREA)
  • Theoretical Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Evolutionary Biology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
HK05101599A 2001-08-17 2005-02-25 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides HK1069205A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31329001P 2001-08-17 2001-08-17
PCT/IB2002/003324 WO2003016567A2 (en) 2001-08-17 2002-08-19 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides

Publications (1)

Publication Number Publication Date
HK1069205A1 true HK1069205A1 (en) 2005-05-13

Family

ID=23215136

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05101599A HK1069205A1 (en) 2001-08-17 2005-02-25 Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides

Country Status (14)

Country Link
US (5) US7200531B2 (de)
EP (2) EP1448986B1 (de)
JP (2) JP4504015B2 (de)
KR (2) KR100943567B1 (de)
AT (2) ATE428781T1 (de)
AU (2) AU2002330663B2 (de)
CA (2) CA2457783A1 (de)
DE (2) DE60231986D1 (de)
DK (1) DK1417307T3 (de)
ES (1) ES2325247T3 (de)
HK (1) HK1069205A1 (de)
IL (4) IL160407A0 (de)
MX (2) MXPA04001315A (de)
WO (2) WO2003016528A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001074342A2 (en) * 2000-03-31 2001-10-11 Trustees Of Boston University Use of locally applied dna fragments
US20030032610A1 (en) * 1996-06-03 2003-02-13 Gilchrest Barbara A. Method to inhibit cell growth using oligonucleotides
US7087586B2 (en) * 2001-04-24 2006-08-08 Bioniche Life Sciences, Inc. Oligonucleotide compositions and their use to induce differentiation of cells
ATE428781T1 (de) * 2001-08-17 2009-05-15 Bioniche Life Sciences Inc Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose
WO2004014312A2 (en) * 2002-08-08 2004-02-19 Sirna Therapeutics, Inc. Small-mer compositions and methods of use
US20060269924A1 (en) * 2003-04-11 2006-11-30 Trustees Of Boston University Modulation of telomere-initiated cell signaling
US20090087456A1 (en) * 2005-09-07 2009-04-02 James Edward Eyles Adjuvanted vaccine
GB0906234D0 (en) 2009-04-14 2009-05-20 Secr Defence Vaccine
KR100998365B1 (ko) 2009-06-29 2010-12-06 압타바이오 주식회사 치료 효능이 있는 변형핵산 및 구아노신을 함유하는 올리고뉴클레오티드 변형체
CN102791291A (zh) * 2009-11-10 2012-11-21 拜昂尼科生命科学有限公司 含有非dna碱基的多核苷酸组合物和其用于调节免疫反应的用途
CN106709925A (zh) * 2016-12-30 2017-05-24 上海联影医疗科技有限公司 医学图像中椎块的定位方法及其装置
CN107704697B (zh) * 2017-10-18 2019-08-20 西南交通大学 一种型材三维拉弯成形性预测评价优化方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5106727A (en) * 1989-04-27 1992-04-21 Life Technologies, Inc. Amplification of nucleic acid sequences using oligonucleotides of random sequences as primers
WO1993018187A1 (en) * 1992-03-13 1993-09-16 California Institute Of Technology Triple helix recognition of dna
US5962426A (en) * 1993-06-25 1999-10-05 Yale University Triple-helix forming oligonucleotides for targeted mutagenesis
DK0805876T3 (da) * 1995-01-19 2000-11-06 Gen Probe Inc Nukleinsyreamplifikationsoligonukleotider og prober til Lyme-sygdom-associeret Borrelia
US5643890A (en) * 1995-01-31 1997-07-01 The Board Of Regents Of The University Of Nebraska Synthetic oligonucleotides which mimic telomeric sequences for use in treatment of cancer and other diseases
EP1171634B1 (de) * 1999-04-08 2005-10-26 Gen-Probe Incorporated Amplifikation und sequenzierung von primer-paaren und deren verwendung
HUP0300627A3 (en) * 1999-12-13 2005-11-28 Bioniche Life Sciences Inc Bel Therapeutically useful synthetic oligonucleotides
WO2003070888A2 (en) * 2002-02-20 2003-08-28 Sirna Therapeutics, Inc. Rna interference mediated inhibition of checkpoint kinase-1 (chk-1) gene expression using short interfering nucleic acid
ATE428781T1 (de) * 2001-08-17 2009-05-15 Bioniche Life Sciences Inc Oligonukleotid-zusammansetzungen und deren verwendung zur induzierung von apoptose

Also Published As

Publication number Publication date
ATE428781T1 (de) 2009-05-15
US8350016B2 (en) 2013-01-08
JP4504015B2 (ja) 2010-07-14
WO2003016528A3 (en) 2003-10-09
US20080077372A1 (en) 2008-03-27
EP1417307B1 (de) 2009-04-15
EP1448986A2 (de) 2004-08-25
AU2002326067B2 (en) 2007-05-31
JP4469603B2 (ja) 2010-05-26
JP2005521119A (ja) 2005-07-14
JP2005509411A (ja) 2005-04-14
IL160408A0 (en) 2004-07-25
IL160407A (en) 2010-02-17
ATE325341T1 (de) 2006-06-15
WO2003016567A2 (en) 2003-02-27
US7199228B2 (en) 2007-04-03
US20030144233A1 (en) 2003-07-31
IL160408A (en) 2010-05-31
US20080081793A1 (en) 2008-04-03
KR101017483B1 (ko) 2011-02-25
US20030113763A1 (en) 2003-06-19
DE60211206T2 (de) 2006-10-26
KR20040032925A (ko) 2004-04-17
ES2325247T3 (es) 2009-08-31
AU2002330663B2 (en) 2007-09-20
WO2003016528A2 (en) 2003-02-27
KR20040030138A (ko) 2004-04-08
DE60231986D1 (de) 2009-05-28
DK1417307T3 (da) 2009-07-13
IL160407A0 (en) 2004-07-25
WO2003016567A3 (en) 2004-06-03
MXPA04001315A (es) 2004-05-20
US20110160291A1 (en) 2011-06-30
US7893242B2 (en) 2011-02-22
CA2457789A1 (en) 2003-02-27
EP1448986B1 (de) 2006-05-03
EP1417307A2 (de) 2004-05-12
CA2457783A1 (en) 2003-02-27
US7200531B2 (en) 2007-04-03
MXPA04001480A (es) 2004-05-20
KR100943567B1 (ko) 2010-02-22
DE60211206D1 (de) 2006-06-08

Similar Documents

Publication Publication Date Title
HK1069205A1 (en) Conformation-activity relationship of apoptosis-inducing phosphodiester oligonucleotides
DE69233599T2 (de) Unterbrochene 2'-modifizierte Oligonukleotide
KR101126030B1 (ko) 사이토킨 및/또는 화학치료제 또는 방사선 치료와 연계하여면역자극 올리고누클레오티드 및/또는 이뮤노머 화합물을이용하여 면역계를 공동 상승 자극시키는 방법
CN101379195B (zh) 含有不同长度回文片段的回文免疫调节性寡核苷酸(imotm)的免疫刺激活性
CA2457485A1 (en) Combination motif immune stimulatory oligonucleotides with improved activity
ATE312202T1 (de) Menschliche rnase h und entsprechende oligonukleotidverbindungen
DK1470144T3 (da) Oligonukleotider omfattende alternerende segmenter og anvendelser deraf
US20060270624A1 (en) Gapped 2' modified oligonucleotides
DK0691980T3 (da) 7-deazapurinmodifiderende oligonukleotider
AU2003243409A8 (en) Method for treating autoimmune or inflammatory diseases with combinations of inhibitory oligonucleotides and small molecule antagonists of immunostimulatory cpg nucleic acids
BR0311343A (pt) Derivados de piridazina
ES2118593T3 (es) Analogos de nucleotidos de pteridina como sondas fluorescentes de adn.
IL173888A0 (en) Novel tricyclic nucleosides or nucleotides as therapeutic agents
DE69931029D1 (de) Optimierte antisense oligonukleotide komplementär zu dna-methyltransferase sequenzen
WO2003048315A3 (en) Antisense modulation of mdm2 expression
WO2001032832A3 (en) Antisense inhibition of nucleolin expression
Polushin et al. On the rapid deprotection of synthetic oligonucleotides and analogs
SE9503117D0 (sv) Novel use of padlock probes
WO2001060998A3 (en) Small oligonucleotides with anti-tumor activity
Grajkowski et al. Design and development of thermolytic DNA oligonucleotide prodrugs
DE60208400D1 (de) Therapeutisch verwendbare triethylenglykol-cholesteryl-oligonukleotide
DK1537210T3 (da) Decoy-oligonukleotid-inhibering af CD40-ekspression
DE69928543D1 (de) Pteridine-nukleotid-analoge
WO2003106646A3 (en) ANTISENSE MODULATION OF DOUBLE SPECIFIC PHOSPHATASE 4 EXPRESSION

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: ADDITION OF INVENTOR: READER, STEPHANIE

PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20130819